Bracco Expands Ultrasound Contrast Agent Production
Bracco has announced a significant investment towards enhancing its capacity to produce contrast agents used in ultrasound imaging, fundamentally increasing the volume of CEUS microbubbles available for medical use.
Innovating Patient Care
This innovative imaging technology assists healthcare professionals worldwide in obtaining more precise diagnostic information, helping to personalize treatment plans and ultimately enhancing patient outcomes.
Investment in Modern Manufacturing Facility
With over 80 million euros invested, the new facility named Hexagon is located adjacent to Bracco's original 1997 plant. Once operational, it will enable the expansion of their innovative ultrasound contrast agent based on microbubble technology, facilitating real-time diagnosis with improved versatility and sustainability.
Continuing Legacy of Bracco
Bracco's legacy illustrates a long-standing commitment to healthcare innovation. Founded in 1927, the company has grown significantly, now operating in 100 countries with a turnover of 1.8 billion euros and more than 3,800 employees.
Strengthening Ties with Switzerland
The deep-rooted connection between Bracco and Switzerland dates back decades, highlighted by the establishment of the Research Center nearly 40 years ago, followed by the current manufacturing site. This collaboration is exemplified in the partnership with the Swiss Battelle Institute, which explored advanced modalities in diagnostic imaging, according to Diana Bracco, the President and CEO of the group.
Pioneering Research and Development
With an average of 12.5 million francs invested per year in research and development at the Geneva facility, Bracco employs a dedicated team of over 45 scientists and researchers, ensuring a close relationship between R&D and production, which is vital for the company's success.
Benefits of Contrast-Enhanced Ultrasound
CEUS stands out as a non-invasive diagnostic tool free from radiation, enhancing visualization of heart chambers, blood vessels, and tissue vascularity. Microbubbles demonstrate potential in precision medicine by serving as carriers for drugs, optimizing their delivery and therapeutic effects.
Bracco's Vision for the Future
Fulvio Renoldi Bracco, Vice Chairman and CEO of Bracco Imaging, emphasized the company's ambition to become the global leader in the CEUS market. With this facility, Bracco aims to integrate its microbubble technology alongside X-ray and MRI innovations, thus altering healthcare delivery to its patients. The company anticipates further advancements in this area as they continue to see promising results globally.
Inauguration Ceremony Highlights
The inauguration of the new facility showcased a modern design focused on sustainability. Attended by key figures such as Anne Lévy, Director of the Federal Office of Public Health, and various ambassadors, the ceremony underscored the strong relations between Italy and Switzerland and celebrated Bracco’s influence in the life sciences sector.
Scientific Symposium: Bubble Power
The day's events included a scientific symposium named "Bubble Power – Imaging & Beyond" at the Spark Auditorium. Various industry experts presented, including Cristina Messa and Thierry Bettinger, providing insights into the future of diagnostic imaging.
Bracco: A Global Leader in Healthcare
As a global healthcare group active in over 100 countries, Bracco specializes in diagnostic imaging and has garnered substantial international sales revenue, representing 88% of its turnover. The company allocates around 10% of its reference turnover to R&D, retaining a robust portfolio of over 2,600 patents in imaging diagnostics and medical devices.
Frequently Asked Questions
1. What is Bracco's new facility aimed at achieving?
The new facility aims to triple the production of ultrasound contrast agents, improving availability in the global market.
2. How does contrast-enhanced ultrasound work?
CEUS utilizes microbubbles to enhance imaging qualities, helping to visualize anatomical structures without radiation exposure.
3. What has been the historical significance of Bracco's research?
Bracco has a long-standing commitment to innovative diagnostic imaging, fostering partnerships that drive medical advancements.
4. How will this investment affect patient diagnostics?
The investment will significantly improve production capacity and accessibility, leading to better diagnostic options for patients.
5. What role does research and development play in Bracco's operations?
R&D is crucial for Bracco's growth strategy, ensuring innovation and quality in its product offerings while maintaining competitive advantage.
